BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25010624)

  • 1. Pathological evaluation of differentiated thyroid cancer in patients with positive serum thyroglobulin and negative iodine scan.
    Ansari M; Babaei AA; Shafiei B; Javadi H; Assadi M; Nabipour I; Asli IN
    Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1925-9. PubMed ID: 25010624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
    Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
    J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
    Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
    Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
    Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.
    Chen P; Feng HJ; Ouyang W; Wu JQ; Wang J; Sun YG; Xian JL; Huang LH
    Endocr Pract; 2016 Sep; 22(9):1048-56. PubMed ID: 27124694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
    Ozkan E; Aras G; Kucuk NO
    Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
    Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
    Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
    J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rare case report of very low thyroglobulin and a negative whole-body scan in a patient with a solid variant of papillary thyroid carcinoma with distant metastases.
    Li W; Sun D; Ming H; Zhang G; Tan J
    Medicine (Baltimore); 2017 Feb; 96(7):e6086. PubMed ID: 28207517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
    Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
    Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan.
    Chao M
    Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):438-47. PubMed ID: 20561773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact factors for the outcome of the first
    Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.